Vir Biotechnology recently announced it will present data from its Phase 2 SOLSTICE trial of the tobevibart-elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, ...

Gilead Sciences received accelerated approval for a chronic hepatitis delta virus treatment from the Food and Drug Administration. The FDA said the Hepcludex treatment, known also as bulevirtide-gmod, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated ...

Not all high-yield ETFs are built the same. In the case of the two major high-dividend yield funds from iShares and Vanguard, there's a clear winner.

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) shares rose 2.5% Friday after the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta ...

The Schwab U.S. Dividend Equity ETF (SCHD) and the iShares Core High Dividend ETF (HDV) are two of the best high-yield equity products out there.

Why should anyone buy dividend stocks? Dividend stock ETFs offer you the chance to own consistently profitable companies that are expected to deliver steady dividend income. There are no guarantees ...

SPYD's simplistic yield-focused strategy lacks robust quality filters, resulting in larger drawdowns and inferior ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study ...

The Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) and the iShares Core High Dividend ETF (NYSEMKT: HDV) are two of the most widely held high-income equity exchange-traded funds (ETFs) in the ...